健尔圣

GenSheng Pharmaceutical is a China-based biopharmaceutical company focused on the development and commercialization of innovative therapies for metabolic diseases, particularly type 2 diabetes and obesity. The company leverages its expertise in peptide chemistry and small molecule drug discovery to build a pipeline of next-generation metabolic regulators. GenSheng is notably involved in the development of GLP-1 receptor agonists and other incretin-based therapies. Headquartered in Zhejiang province, the company operates integrated R&D and manufacturing facilities to support its clinical programs. Their strategic focus remains on addressing the growing global burden of metabolic syndrome through high-quality, accessible pharmaceutical solutions.